1 Isotretinoin 5 mg daily for low-grade adult acne vulgaris - a placebo-controlled, randomized double-blind study Journal of the European Academy of Dermatology and Venereology, April 29, 2013
2 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, May 3, 2013
3 Salicylic Acid Peel Incorporating Triethyl Citrate and Ethyl Linoleate in the Treatment of Moderate Acne: A New Therapeutic Approach Dermatologic Surgery, May 1, 2013
4 Most common patterns of acne in male adolescents: a population-based study International Journal of Dermatology, April 24, 2013 Review Article
5 ANA (+) ANCA (+) systemic vasculitis associated with the use of minocycline: case-based review Clinical Rheumatology, April 22, 2013 Review Article
6 What is the role of antimicrobial peptides (AMP) in acne vulgaris Experimental Dermatology, April 30, 2013
7 Bacterial recolonization of the skin and wound contamination during cardiac surgery: a randomized controlled trial of the use of plastic adhesive drape compared with bare skin Journal of Hospital Infection, May 3, 2013 Review Article
8 Safety and efficacy of tazarotene foam for the treatment of acne vulgaris Clinical, Cosmetic and Investigational Dermatology, May 14, 2013 Review Article
9 Severe destruction of the temporomandibular joint with complete resorption of the condyle associated with synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, May 13, 2013 Review Article
10 Fairview, Zipnosis partner for quick, online diagnosis Fairview Health Services, May 6, 2013
Sponsor
Register now to view all the MDLinx contents (FREE)!
Login
Sponsor
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close
Sponsor